🔗 Share this article

A shadow market for unlicensed weight-loss drugs is propelled by social media fitness personalities and vendors on messaging platforms, according to recent findings.

Experimental Treatment Gaining Traction Online

The experimental drug, which is still in research studies, is being promoted by online personalities for its supposed weight-reducing effects. Viewers are encouraged to contact these profiles directly for source information, while also receiving discount codes.

Thriving Commerce on Messaging Platforms

Separately, a robust market exists on messaging services, where groups with thousands of members share comparison photos, administration instructions and claims of next-day British shipping. Sellers market the substance there before redirecting customers to WhatsApp for transactions.

Understanding The Experimental Drug

Retatrutide is an investigational injectable created by US drugmaker Eli Lilly. The drug affects three intestinal hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies suggest it could assist patients reduce up to 25% of their total weight. Referred to as the “triple G”, the substance is being promoted online as the next Ozempic.

Healthcare Professionals Express Worries

However, physicians and chemists have warned that the distribution of what remains an unapproved drug in the United Kingdom is a cause for concern and could lead to individuals administering products of uncertain source.

Several professionals stated the demand for retatrutide could be linked to the increasing price of approved slimming treatments such as Mounjaro.

Legal Position and Enforcement

Selling retatrutide on TikTok or messaging apps is prohibited in the UK, as it is an unapproved medication that must not be promoted or supplied for human use under the Human Medicines Regulations 2012.

Some content creators attempt to circumvent the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and supply can still violate medicines, advertising, and customer regulations, risking fines, legal action or imprisonment.

Service Response and Material Elimination

According to the social media company, the service has removed violative material and prohibited associated hashtags and query recommendations. The company said it was dedicated to maintaining the service safe and investing in enhancing enforcement strategies.

Digital Trading Operations

Investigations also found groups with up to nine thousand participants marketing retatrutide using the platform's built-in discovery tool, which operates like a online catalog. Entering “retatrutide” immediately displays groups with thousands of members, filled with photos of weight loss, positive testimonials and step-by-step instructions for mixing or injecting at residence.

Within minutes of joining one community, a vendor posted contact information, where most purchases take place. The seller provided an guidebook and promised delivery within two days. When questioned whether the substance was authentic, one seller responded: “You can’t be sure.” Another shared a photo of a supposed testing documentation. None inquired about body mass, medical conditions or past usage.

Product Information and Costs

Inside these communities, messages show black plastic parcels with postal service stickers, claiming to include new batches. One message read: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, mixed at home with purified liquid, or pre-filled pens usually priced at £160 for 20 milligrams. When asked how long a pen should be used, sellers give contradictory answers ranging from a few weeks to “depends on your body”.

Platform Oversight and Security Actions

A spokesperson for the messaging service stated it actively moderated dangerous material on its service including content that encouraged the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Cautions

“Individuals are administering substances they cannot confirm. Although the science behind this drug is sound, these digital versions may not contain what they claim,” said Jason Murphy, the director of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in demand to current cost increases for approved slimming drugs such as Mounjaro. “With prices increasing, individuals are using online platforms. But fake treatments are extremely dangerous. You can’t be certain what’s inside or whether the environment they were produced in was sterile,” she said.

Her staff has already seen patients injured by self-injection from unverified sources. “We recognize the disappointment, but purchasing from Telegram or communication platforms is taking chances with your well-being,” said the doctor. “These substances could be contaminated or improperly measured.”

Manufacturer Statement

A representative from the pharmaceutical company stated retatrutide was in phase 3 clinical trials and had not been evaluated or authorized by any government authority anywhere in the world. “Consequently at this time no one can market [it] for personal consumption,” they explained, noting that any product “falsely representing itself as a Lilly experimental substance not yet approved … may expose users to potentially serious medical dangers”.